Lenalidomide hemihydrate

• CAT Number: I005076
• CAS Number: 847871-99-2
• Molecular Formula: C26H28N6O7
• Molecular Weight: 536.54
• Purity: ≥95%
• Synonyms: 4-amino-2-(6-hydroxy-2-oxo-2,3,4,5-tetrahydropyridin-3-yl)isoindolin-1-one hydrate
• Target: TNF-α
• Solubility: 10 mM in DMSO
• Storage: Store at -20C
• IC50: 13 nM [1]

Lenalidomide hemihydrate (Cat.No:I005076) is a pharmaceutical compound that belongs to the class of immunomodulatory drugs. It is used in the treatment of multiple myeloma, myelodysplastic syndromes, and certain types of lymphoma. Lenalidomide hemihydrate works by modulating the immune system and inhibiting the growth of cancer cells. It is typically administered orally and requires medical supervision.

Reference

[1]. Muller GW, et al. Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production. Bioorg Med Chem Lett. 1999 Jun 7;9(11):1625-30.
[2]. Zangari M, et al. Immunomodulatory drugs in multiple myeloma. Expert Opin Investig Drugs. 2005 Nov;14(11):1411-8.
[3]. Lopez-Girona A, et al. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia. 2012 Nov;26(11):2326-35.
[4]. Rozewski DM, et al. Pharmacokinetics and tissue disposition of lenalidomide in mice. AAPS J. 2012 Dec;14(4):872-82.
[5]. Danbara M, et al. Lenalidomide-induced acute lung injury in case of multiple myeloma. Int J Clin Pharmacol Ther. 2013 Jun;51(6):513-6.